公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2011 | T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement | SUNG-HSIN KUO ; ANN-LII CHENG ; CHUNG-WU LIN ; CHIH-HUNG HSU ; MING-SHIANG WU ; KUN-HUEI YEH ; Tzeng Y.-S.; Chen L.-T. | Cancer Chemotherapy and Pharmacology | 13 | 8 | |
2018 | Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma | Chang C.-J.; YAO-HSU YANG ; Chiu C.-J.; LI-CHUN LU ; Liao C.-C.; Liang C.-W.; CHIH-HUNG HSU ; ANN-LII CHENG | International Journal of Cancer | 42 | 37 | |
2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 | |
1997 | Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin | CHIH-HUNG HSU ; KUN-HUEI YEH ; ANN-LII CHENG | Anticancer Research | 18 | 17 | |
2022 | Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer | Doki Y.; Ueno M.; CHIH-HUNG HSU ; Oh D.-Y.; Park K.; Yamamoto N.; Ioka T.; Hara H.; Hayama M.; Nii M.; Komuro K.; Sugimoto M.; Tahara M. | Cancer Medicine | 20 | 16 | |
2021 | Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma | CHIH-HORNG WU ; PO-CHIN LIANG ; CHIH-HUNG HSU ; Chang, Fang-Tsu; YU-YUN SHAO ; TIFFANY TING-FANG SHIH | Journal of the Formosan Medical Association = Taiwan yi zhi | 21 | 17 | |
2015 | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | YU-YUN SHAO ; Shau, W.-Y.; Chan, S.-Y.; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 29 | 29 | |
2000 | Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel | CHIH-HUNG HSU ; Chen M.-Y.; ANN-LII CHENG | Anticancer Research | 6 | 4 | |
2016 | Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges | LI-CHUN LU ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG | Liver Cancer | 95 | 98 | |
2016 | Tumor-associated neutrophils: An emerging player in the immune microenvironment of hepatocellular carcinoma | LI-CHUN LU ; CHIH-HUNG HSU | Translational Cancer Research | 2 | 2 | |
2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 19 | 17 | |
2011 | Ump/cmpk is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human rko cells | Hu R.; Lam W.; CHIH-HUNG HSU ; Cheng Y.-C. | PLoS ONE | 6 | 6 | |
2021 | An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 7 | 5 | |
2021 | The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Lee J.-M.; Yang M.-H.; Chao Y. | Journal of the Formosan Medical Association | 4 | 4 | |
1997 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers | CHIH-HUNG HSU ; KUN-HUEI YEH ; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | Oncology (Switzerland) | 60 | 51 | |
2008 | Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation | TA-CHEN HUANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU | Anticancer Research | 15 | 9 | |
2006 | Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU | Cancer | 24 | 24 | |
2004 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract | CHIUN HSU ; Ying-Chun Shen ; CHIH-HSIN YANG ; KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG | British Journal of Cancer | 42 | 40 | |
2007 | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | CHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU | Urologic Oncology: Seminars and Original Investigations | 6 | 6 | |
2014 | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Lee Y.-H.; MIN-SHU HSIEH ; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO ; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology (Switzerland) | 25 | 24 | |